Our results further indicated that enforced IGF2BP3 expression significantly reduced the ability of BET inhibitors to reduce tumor survival (Supplementary Fig. 6i–k), extend survival time (Supplementary Fig. 6l), and inhibit NETosis (Supplementary Fig. 6m, n). This evidence concerns the gene IGF2BP3 and neoplasm.